MedPath

Atridia Pty Ltd.

🇦🇺Australia
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

30

Active:0
Completed:26

Trial Phases

2 Phases

Early Phase 1:1
Phase 1:29

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials

Phase 1
29 (96.7%)
Early Phase 1
1 (3.3%)

A Trial of HRS-1893 in Healthy Volunteers

Phase 1
Recruiting
Conditions
Hypertrophic Cardiomyopathy
Interventions
First Posted Date
2025-06-24
Last Posted Date
2025-06-29
Lead Sponsor
Atridia Pty Ltd.
Target Recruit Count
20
Registration Number
NCT07033455
Locations
🇦🇺

Linear Clinical Research, Nedlands, Western Australia, Australia

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Phase 1
Recruiting
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Drug: HRS-5041 Single dose of HRS-5041 orally administered
First Posted Date
2025-02-17
Last Posted Date
2025-07-03
Lead Sponsor
Atridia Pty Ltd.
Target Recruit Count
25
Registration Number
NCT06830850
Locations
🇦🇺

GenesisCare North Shore (Oncology), Sydney, New South Wales, Australia

🇦🇺

Sydney Adventist Hospital, Sydney, New South Wales, Australia

🇦🇺

Cancer Research SA, Adelaide, South Australia, Australia

and more 8 locations

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
Drug: HRS-5041 dose level 1
Drug: HRS-5041 dose level 2
First Posted Date
2024-08-19
Last Posted Date
2025-03-18
Lead Sponsor
Atridia Pty Ltd.
Target Recruit Count
24
Registration Number
NCT06559007
Locations
🇦🇺

Nucleus Network Melbourne, Melbourne, Victoria, Australia

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

Phase 1
Withdrawn
Conditions
HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
Interventions
First Posted Date
2024-08-19
Last Posted Date
2025-01-07
Lead Sponsor
Atridia Pty Ltd.
Target Recruit Count
20
Registration Number
NCT06560138
Locations
🇦🇺

Scientia Clinical Research Limited, Randwick, New South Wales, Australia

🇦🇺

Macquarie University, Sydney, New South Wales, Australia

🇦🇺

Icon Cancer Centre South Brisbane, Brisbane, Queensland, Australia

and more 2 locations

Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians

Early Phase 1
Completed
Conditions
MRI
Interventions
Drug: HRS-9231or matching placebo
First Posted Date
2024-07-25
Last Posted Date
2024-12-06
Lead Sponsor
Atridia Pty Ltd.
Target Recruit Count
20
Registration Number
NCT06519981
Locations
🇦🇺

Linear Clinical research, Perth, Western Australia, Australia

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath